Novartis registers two Phase I trials: TRB191 in SCLC and XEP527 in schizophreniaNov 6Weekly roundup, 10 itemsArdtartemether and lumefantrine
Kairos Pharma signs research agreement with Bayer to test ENV-105 with XOFIGO in prostate cancerJul 22Clinical readoutKairos Pharma, LTD.radium ra 223 dichloride